戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  labeling was protected by a molar excess of famotidine.
2 ated pH relevant for absorption and DDI with famotidine.
3 -generated randomisation sequence to receive famotidine 20 mg twice daily (n=204) or placebo twice da
4 y used agents for SUP were ranitidine (31%), famotidine (24%), sucralfate (24%), and cimetidine (12%)
5    We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor ant
6 r PL(pro), as potential molecular targets of famotidine activity; however, this remains to be experim
7        Recommended over-the-counter doses of famotidine and calcium carbonate tablets have different
8 -19 treatment, including hydroxychloroquine, famotidine, and dexamethasone.
9 inistration of diphenhydramine, epinephrine, famotidine, and/or hydrocortisone, used as surrogate mak
10 e in AUC and C(max) between pentagastrin and famotidine arms, thereby effectively mitigating the impa
11                       These results rule out famotidine as a direct-acting inhibitor of SARS-CoV-2 re
12 ected ranitidine for ease of administration, famotidine because of formulary availability, sucralfate
13 model of pH dependence, preadministration of famotidine caused a 2.4-fold lower exposure of 1 when co
14         The H(2) antagonists, ranitidine and famotidine, exhibit saturable absorptive transport acros
15         As the case study, the solubility of famotidine (FAM) medicine in sc-CO(2) (supercritical car
16       There were fewer adverse events in the famotidine group than in the placebo group (nine vs 15);
17                                              Famotidine had a delayed onset of action compared with a
18                                     However, famotidine had a duration of effect of at least 540 minu
19                A photoreactive derivative of famotidine has been synthesized and evaluated as a photo
20                                              Famotidine is effective in the prevention of gastric and
21  other most common adverse event was angina (famotidine, n=2; placebo, n=4).
22                                 82 patients (famotidine, n=33; placebo, n=49) did not have the final
23 ophysical and enzymatic assays, we show that famotidine neither binds with nor inhibits the functions
24 rt, we systematically analyzed the effect of famotidine on viral proteases and virus replication.
25  reflective of acid secretion inhibited by a famotidine or acid neutralized by calcium carbonate tabl
26                       H2 R was blocked using famotidine or activated using dimaprit in both the ovalb
27 ho received at least one dose of study drug (famotidine or placebo).
28                                       H2RAs (famotidine) or PPIs (pantoprazole, omeprazole, esomepraz
29  received the histamine2-receptor antagonist famotidine (Pepcid AC, 10 mg), calcium carbonate antacid
30 ak effect, 210 minutes after administration, famotidine reduced acid secretion by 7.3 mmol per 30 min
31 stamine receptor antagonists (pyrilamine and famotidine, respectively) greatly diminishes recruitment
32             A sensitivity analysis comparing famotidine to pantoprazole confirmed this finding (OR, 0
33 and cytokine production in H2 R-deficient or famotidine-treated animals, while dimaprit dampened the
34                                              Famotidine treatment resulted in more severe airway dise
35  separate, patient-reported study associated famotidine use with improvements in mild to moderate sym
36   Similarly, no direct antiviral activity of famotidine was observed at concentrations of up to 200 u
37 le, retrospective clinical study showed that famotidine, when administered at a high dose to hospital
38  At 12 weeks, comparing patients assigned to famotidine with patients assigned to placebo, gastric ul